Axsome Therapeutics
AXSM
35 hedge funds and large institutions have $10.8M invested in Axsome Therapeutics in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 10 closing their positions.
351% more call options, than puts
Call options by funds: $284K | Put options by funds: $63K
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
0% more funds holding
Funds holding: 35 → 35 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.63% less ownership
Funds ownership: 13.46% → 12.84% (-0.63%)
12% less capital invested
Capital invested by funds: $12.2M → $10.8M (-$1.4M)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
+$1.19M |
| 2 |
Millennium Management
New York
|
+$1.02M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$823K |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$375K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$243K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.44M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$770K |
| 3 |
OPPM
Opus Point Partners Management
New York
|
-$415K |
| 4 |
JP Morgan Chase
New York
|
-$140K |
| 5 |
SCM
Sio Capital Management
New York
|
-$117K |
AXSM Hedge Fund Activity: Q4 2018 in Review
35 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2018, worth a combined $10.8M — down 12% from $12.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new AXSM positions and 10 closed out — a net gain of 1 holder — while 5 added to existing stakes and 10 trimmed.
The largest buyer was Alethea Capital Management, adding an estimated $1.19M. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.44M sold.
- 35 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $10.8M of Axsome Therapeutics stock for Q4 2018, down 12% quarter-over-quarter.
- 11 funds opened new Axsome Therapeutics positions in Q4 2018 and 10 closed out, a net change of +1 holder.
- The largest Axsome Therapeutics buyer in Q4 2018 was Alethea Capital Management, an estimated $1.19M added.
- The largest Axsome Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $1.44M sold.
Based on aggregated 13F filings for Q4 2018.